COMMUNIQUÉS West-GlobeNewswire

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
26/09/2019
Requisite clinical responses achieved in cohort 1 of Part A (1 st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2 Recruitment of cohort 2 of Part A of TACTI-002, additional 19 [...]
Medtronic Announces New Clinical Trial to Study Infuse Bone Graft in TLIF Spine Procedures
26/09/2019
Medtronic Continues to Invest in Scientific Evidence for Expansion of Indications and Greater Clinical Understanding of Infuse™ Bone Graft DUBLIN and CHICAGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) [...]
PetVivo Holdings, Inc. Featured in New Research Update
26/09/2019
MINNEAPOLIS, MN, Sept. 26, 2019 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity [...]
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
26/09/2019
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of mRNA therapeutics for [...]
RedHill Biopharma Provides H2/2019 R&D Update
26/09/2019
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (Tel-Aviv Stock Exchange: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company [...]
Global Marketing and Strategy Leader Martha Pease Joins BioSig Board of Directors
26/09/2019
Fortune 500 business veteran brings unrivalled expertise in building brands and transformational tech innovation Westport, CT, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device [...]
OpGen to Present on Guiding Precision Antibiotic Therapy with Rapid Genomics and Informatics at IDWeek 2019
26/09/2019
Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software to be highlighted in a conference speaker session GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today that data from [...]
MacroGenics to Participate in Cantor Global Healthcare Conference
26/09/2019
ROCKVILLE, MD, Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
26/09/2019
All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and [...]
Arbutus to Participate in Upcoming Investor Conferences
26/09/2019
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be [...]
SI-BONE, Inc. Announces Publication of Five-Year Prospective Study Results on 103 Patients Treated with Triangular Titanium iFuse Implant System
26/09/2019
Long-term follow-up results show excellent durability of clinical responses and positive radiographic outcomes for SI joint fusion using triangular titanium implants SANTA CLARA, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE [...]
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019
26/09/2019
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, [...]
U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile
26/09/2019
$14 million in non-dilutive capital added by year end RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and [...]
Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
26/09/2019
REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare [...]
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
26/09/2019
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration
26/09/2019
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application ( [...]
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
26/09/2019
SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl [...]
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019
26/09/2019
YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins [...]
OptiNose Announces License Agreement Related to ONZETRA XSAIL
26/09/2019
YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the [...]

Pages